Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2

Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2

B-cell and T-cell lymphomas and leukemias often have distinct genetic mutations that are diagnostically defining or prognostically significant. A subset of these mutations consists of specific point mutations, which can be evaluated using genetic sequencing approaches or point mutation specific anti...

Full description

Bibliographic Details
Main Authors: Kunwar Singh, Sumanth Gollapudi, Sasha Mittal, Corinn Small, Jyoti Kumar, Robert S. Ohgami
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Diagnostics
Subjects:
single nucleotide polymorphisms
hematopathology
cancer
diagnostics
point mutation specific antibodies
precision medicine
Online Access:https://www.mdpi.com/2075-4418/11/4/600

Internet

https://www.mdpi.com/2075-4418/11/4/600

Similar Items